China HeadAche DIsorders RegiStry
Beijing Tiantan Hospital
10,000 participants
Aug 29, 2022
OBSERVATIONAL
Conditions
Summary
It is planned to include 10000 patients. In the China HeadAche DIsorders RegiStry CHAIRS）, patients aged over 12 years with primary headache and medication-overuse headache(MOH) were collected. The biomarkers, imaging features, cognition, genetic characteristics, ocial and demographic data, medical data, therapeutics used, and outcome of headache-related diseases were studied, and long-term follow-up was planned.
Eligibility
Inclusion Criteria4
- Age ≥ 12 years old,Any gender;
- The first onset age of primary headache was less than 50 years old(Age <65 years at first diagnosis of chronic migraine);
- patients with primary headache (migraine, tension headache and other types of primary headache) or primary headache complicated with MOH according to ICHD-3;
- Sign the informed consent form.
Exclusion Criteria7
- According to the ICHD-3 diagnostic criteria, there are still headaches directly related to secondary factors (except drug overuse) at the time of enrollment;
- Those who cannot be diagnosed as primary headache or primary headache combined with medication overuse headache according to ICHD-3;
- According to DSM-V diagnostic criteria, patients with severe mental diseases (such as schizophrenia, mental disorders associated with mental retardation, etc.);
- Patients with severe organic diseases, such as malignant tumors, and the expected survival time is less than 1 year;
- Pregnant,planning pregnancy or Lactating women;
- Subjects participating in other clinical trials;
- Unable to cooperate to complete the follow-up due to geographical or other reasons
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
At the end of the 24th month visit, the patient is free to choose whether to conduct a face-to-face visit once a year until death.
long-term follow-up
No collection Brain imaging、Cognitive function test、Biological sample
Participants who, in routine clinical practice, were prescribed Yangxue Qingnao Granules/Pills for acute headache relief and/or preventive management were enrolled. Treatment initiation, dosing, frequency, and duration were determined by the treating physician and the patient and were not assigned by the study protocol. During the 12-week observation period, participants were followed and outcomes were recorded, including relief of up to four headache episodes (for those using the medication for acute treatment) and longitudinal symptom measures at weeks 4, 8, and 12 (for those receiving preventive management).
Participants who received eptinezumab for migraine prophylaxis in routine clinical practice were included. Treatment decisions (including whether to initiate eptinezumab, the selected dose \[e.g., 100 mg or 300 mg\], infusion interval, and duration) were made by the treating physician in consultation with the patient, and were not assigned by the study protocol. Patients were followed prospectively/retrospectively according to routine clinic visits, with outcome assessments captured at approximately 4-week intervals during the 12-week observation window (and additional follow-up when available).
Participants who received eptinezumab for migraine prophylaxis in routine clinical practice were included. Treatment decisions (including whether to initiate eptinezumab, the selected dose \[e.g., 100 mg or 300 mg\], infusion interval, and duration) were made by the treating physician in consultation with the patient, and were not assigned by the study protocol. Patients were followed prospectively/retrospectively according to routine clinic visits, with outcome assessments captured at approximately 4-week intervals during the 12-week observation window (and additional follow-up when available).
Locations(61)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05334927